目的 探讨益脑复健胶囊联合依达拉奉注射液治疗急性脑梗死的临床疗效。方法 选取2019年4月—2021年12月在南阳市第一人民医院接受治疗的96例急性脑梗死患者，采用信封抽签法将患者分为对照组和治疗组，每组各48例。对照组静脉滴注依达拉奉注射液，30 mg溶于150 mL生理盐水中，半小时内滴注结束，1次/d。治疗组在对照组的基础上口服益脑复健胶囊，3～4粒/次，3次/d。两组均治疗14 d。观察两组临床疗效，比较两组的神经功能缺损情况、脑血流动力指标、血液流变学指标和神经递质。结果 治疗后，治疗组的总有效率为91.67%，高于对照组的总有效率75.00%（P＜0.05）。治疗后，两组美国国立卫生研究院卒中量表（NIHSS）评分均显著下降（P＜0.05），且治疗组NIHSS评分明显低于对照组（P＜0.05）。治疗后，两组大脑动脉血流最大峰值（V_s）、平均流速（V_m）均显著升高，血管阻力指数（RI）显著下降（P＜0.05），治疗组V_s、V_m均显著高于对照组，RI均显著低于对照组（P＜0.05）。治疗后，两组血小板聚集率、血浆黏度、血细胞比容、纤维原蛋白均显著下降（P＜0.05），且治疗组血小板聚集率、血浆黏度、血细胞比容、纤维原蛋白均明显低于对照组（P＜0.05）。治疗后，两组血清神经元特异性烯醇化酶（NSE）、S100β蛋白水平显著下降（P＜0.05），且治疗组血清NSE、S100β蛋白水平显著低于对照组（P＜0.05）。结论 益脑复健胶囊联合依达拉奉注射液治疗急性脑梗死具有较好的临床疗效，可减轻神经功能缺损，改善机体血液流变学，减轻机体应激反应，改善神经递质水平分泌，具有较好的临床应用价值。

Objective To explore the clinical effect of Yinao Fujian Capsules combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients (96 cases) with acute cerebral infarction in Nanyang First People’s Hospital from April 2019 to December 2021 were divided into control and treatment groups according to the envelope drawing method, and each group had 48 cases. Patients in the control group were iv administered with Edaravone Injection, 30 mg added into normal saline 150 mL, completed the infusion within half an hour, once daily. Patients in the treatment group were po administered with Yinao Fujian Capsules on the basis of the control group, 3 — 4 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the neurological deficit, cerebral hemodynamics, hemorheology, and neurotransmitters in two groups were compared. Results After treatment, the total effective rate of the treatment group was 91.67%, which was higher than that of the control group (75.00%, P < 0.05). After treatment, the scores of NIHSS in two groups were significantly decreased (P < 0.05), and the scores of NIHSS in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, V_s and V_m in two groups were significantly increased, but RI in two groups was significantly decreased (P < 0.05). V_s and V_m in the treatment group were significantly higher than those in the control group, but RI in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the platelet aggregation rate, plasma viscosity, hematocrit, and fibrinogen in two groups were significantly decreased, and these indexes in the treatment group were lower than those in the control group (P < 0.05). After treatment, the serum levels of NSE and S100β protein in two groups were significantly decreased (P < 0.05), and the serum levels of NSE and S100β protein in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Yinao Fujian Capsules combined with Edaravone Injection has a significant effect in treatment of acute cerebral infarction, can reduce the neural function defect, improve the hemorheology of the body, reduce the stress response of the body, and improve the secretion of neurotransmitters, which has good clinical application value.

R971

河南省科技发展计划项目（182102320664）